CBLB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3827059	0.77	19/20
SCHEMBL3824319	0.77	19/20
SCHEMBL3823622	0.69	19/20
SCHEMBL1506083	0.58	19/20
SCHEMBL1505971	0.58	19/20
SCHEMBL1505988	0.56	19/20
SCHEMBL1505876	0.56	18/20
SCHEMBL3824081	0.75	17/20
SCHEMBL3824296	0.75	17/20
SCHEMBL5606392	0.74	17/20
SCHEMBL3823312	0.70	17/20
SCHEMBL3823321	0.70	17/20
SCHEMBL3823569	0.66	17/20
SCHEMBL3822275	0.65	17/20
SCHEMBL3829298	0.64	17/20
SCHEMBL3823065	0.54	17/20
SCHEMBL945431	0.47	17/20
SCHEMBL944064	0.46	16/20
SCHEMBL3823587	0.66	15/20
SCHEMBL3825668	0.57	15/20

Clinical trials — most relevant to CBLB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Leniolisib for Immune Dysregulation in PIDs	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy	PHASE2	COMPLETED
5G-PEARL: Paxalisib in Malignant Brain Tumours	PHASE1/PHASE2	RECRUITING
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas	PHASE1	COMPLETED
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE	PHASE1	RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001	PHASE1	COMPLETED
Glutamine Supplementation in People With Immune Dysregulation	EARLY_PHASE1	WITHDRAWN
A Window of Opportunity Study of Black Raspberry for Patients With HNSCC	EARLY_PHASE1	WITHDRAWN
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery	EARLY_PHASE1	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients	nan	UNKNOWN
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants.	nan	COMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Novel Genetic Disorders of the Immune System	nan	RECRUITING
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CBLB binder may also engage these)

Protein	Name	Similarity
Q8K4S7	—	1.000	Q8K4S7 →
Q6GQL0	—	1.000	Q6GQL0 →
Q3TTA7	—	1.000	Q3TTA7 →
Q98TY6	—	0.997	Q98TY6 →
Q6NRE7	—	0.997	Q6NRE7 →
CBL	E3 ubiquitin-protein ligase CBL	0.993	landscape →
Q6DFR2	—	0.992	Q6DFR2 →
Q80TJ7	—	0.989	Q80TJ7 →
O54828	—	0.989	O54828 →
Q9H694	—	0.988	Q9H694 →
P22682	—	0.988	P22682 →
Q8BMA3	—	0.985	Q8BMA3 →
O75916	—	0.985	O75916 →
Q9HBD1	—	0.985	Q9HBD1 →
Q62925	—	0.985	Q62925 →
Q8R5H6	—	0.984	Q8R5H6 →
P0CH95	—	0.984	P0CH95 →
Q6A0A9	—	0.984	Q6A0A9 →
Q68EF0	—	0.984	Q68EF0 →
O88974	—	0.984	O88974 →
Q6F6B3	—	0.984	Q6F6B3 →
Q62136	—	0.984	Q62136 →
P49140	—	0.983	P49140 →
Q5BJU7	—	0.983	Q5BJU7 →
Q4VGL6	—	0.983	Q4VGL6 →
A9ZLX4	—	0.983	A9ZLX4 →
Q9BY84	—	0.983	Q9BY84 →
Q5RHD1	—	0.983	Q5RHD1 →
Q9C0H5	—	0.983	Q9C0H5 →
Q924W7	—	0.983	Q924W7 →